Recursion acquires Cyclica ($40M) & Valence ($47.5M); Q1 net loss $65.3M

RECURSION PHARMACEUTICALS, INC.

2023-Q1 EPS reported -$0.34 revenue$12,134,000

Entered agreements to acquire Cyclica for $40M and Valence for $47.5M, payable in stock; expected Q2 2023 close.
Q1 cash $473.1M; revenue $12.1M (up from $5.3M YoY) driven by Roche-Genentech collaboration.
Net loss $65.3M vs $56.0M Q1 2022; R&D expenses rose to $46.7M on platform expansion.
Phase 2 SYCAMORE trial (REC-994) in CCM: >80% enrolled; top-line data expected H2 2024.
Phase 2/3 POPLAR trial (REC-2282) in NF2-mutated meningiomas; interim safety analysis expected 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

RECURSION PHARMACEUTICALS, INC. reported financial results for first quarter March 31, 2023.

Period: first quarter March 31, 2023
Result: reported results

Exact text from the filing

On May 8, 2023, Recursion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the first quarter March 31, 2023.

View on SEC.gov

16 earnings releases filed in the last 30 days. Browse all earnings releases →

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001601830-23-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.